BiotechTube

Somatropin (rDNA origin)

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Turner Syndrome

Conditions

Turner Syndrome, Renal Insufficiency, Chronic, Pituitary Diseases, Dwarfism

Trial Timeline

Jun 1, 2004 → Jul 1, 2008

NCT ID
NCT00234533

About Somatropin (rDNA origin)

Somatropin (rDNA origin) is a phase 3 stage product being developed by Ipsen for Turner Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00234533. Target conditions include Turner Syndrome, Renal Insufficiency, Chronic, Pituitary Diseases.

What happened to similar drugs?

3 of 7 similar drugs in Turner Syndrome were approved

Approved (3) Terminated (0) Active (4)
✅HumatropeEli LillyApproved
✅r-hGHMerckApproved
✅estradiolNovo NordiskApproved
🔄SomatropinEli LillyPhase 3
🔄17 beta estradiolEli LillyPhase 3
🔄Somatropin + Ethinyl estradiol + Medroxyprogesterone acetateEli LillyPhase 3
🔄Somapacitan + Norditropin®Novo NordiskPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00234533Phase 3Completed

Competing Products

10 competing products in Turner Syndrome

See all competitors
ProductCompanyStageHype Score
SomatropinEli LillyPhase 3
40
HumatropeEli LillyApproved
43
17 beta estradiolEli LillyPhase 3
40
Somatropin + Ethinyl estradiol + Medroxyprogesterone acetateEli LillyPhase 3
40
r-hGHMerckApproved
43
Somapacitan + Norditropin®Novo NordiskPhase 3
44
estradiolNovo NordiskApproved
43
Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patchNovo NordiskPhase 1
21
somatotropinPfizerPre-clinical
26
Lonapegsomatropin + SomatropinAscendis PharmaPhase 2
36